newsfilter
← Latest News
GlobeNewswire·

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S